'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Ipca Laboratories has increased 10.51% to Rs 2246.69 crore. Sales of India segment has gone up 10.02% to Rs 911.95 crore (accounting for 40.59% of total sales). Sales of Outside India segment has gone up 10.85% to Rs 1,334.74 crore (accounting for 59.41% of total sales). Operating profit margin has jumped from 15.83% to 19.09%, leading to 33.23% rise in operating profit to Rs 428.86 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 27.96% to 28.88%. Purchase of finished goods cost fell from 5.37% to 3.81%. Employee cost decreased from 23.06% to 21.91%. Other expenses fell from 27.67% to 26.63%.
Other income rose 36.47% to Rs 25.82 crore. PBIDT rose 33.41% to Rs 454.68 crore. ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|